

Trend of CD4+ Cell Counts at Diagnosis and Initiation of Highly Active Antiretroviral Therapy (HAART): Korea HIV/AIDS Cohort Study, 1992-2015

Min Jung Kim¹, Hyun-Ha Chang¹, Sang Il Kim², Youn Jeong Kim², Dae Won Park³, Chun Kang⁴, Mee-Kyung Kee⁴, Ju-yeon Choi⁴, Soo Min Kim⁵, Bo Youl Choi^{5,6}, Woo-Joo Kim⁷, June Myung Kim^{8,9}, Jun Yong Choi^{8,9}, Young Hwa Choi¹⁰, Jin-Soo Lee¹¹, Shin-Woo Kim¹, and Korea HIV/AIDS Cohort Study

¹Department of Internal Medicine, Kyungpook National University, Daegu; ²Division of Infectious Diseases, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul; ³Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul; ⁴Division of AIDS, Korea Centers for Disease Control and Prevention, Cheongju; ⁵Institute for Health and Society, Hanyang University, Seoul; ⁶Department of Preventive Medicine, Hanyang University College of Medicine, Seoul; ⁷Department of Internal Medicine, Korea University College of Medicine, Seoul; ⁸Department of Internal Medicine, Yonsei University College of Medicine, Seoul; ⁹AIDS Research Institute, Yonsei University College of Medicine, Seoul; ¹⁰Department of Infectious Diseases, Ajou University School of Medicine, Suwon; ¹¹Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea

Background: CD4+ cell counts reflect immunologic status of human immunodeficiency virus (HIV) patients. Recommended CD4+ cell counts for the initiation of highly active antiretroviral therapy (HAART) has increased over the past several years in various HIV treatment guidelines. We investigated the trend of CD4+ cell counts at diagnosis and treatment start using data from the Korea HIV/acquired immune deficiency syndrome (AIDS) Cohort Study.

Materials and Methods: The Korea HIV/AIDS Cohort Study started in 2006 and enrolled HIV patients from 21 tertiary and secondary hospitals in South Korea. The data for CD4+ cell counts at diagnosis and HAART initiation from these HIV patients were analyzed by three-year time intervals and presented by number of CD4+ cells (≤ 100 , 101-200, 201-350, 351-500 and > 500 cells/mm³). The HIV-RNA titer at diagnosis and HAART initiation were presented by 3-year intervals by groups $\leq 50,000$, 50,001-100,000, 100,001-200,000, 200,001-1,000,000, and $> 1,000,000$ copies/mL.

Results: Median values of CD4+ cell count and HIV-RNA titer at initial HIV diagnosis were 247 cells/mm³ and 394,955 copies/mL, respectively. At time of initiating HAART, median values of CD4+ cell count and HIV-RNA were 181 cells/mm³ and 83,500 copies/mL, respectively. Patients with low CD4+ cell count (CD4+ cell count ≤ 200 cells/mm³) at diagnosis (31-51%) and initiation of HAART accounted for the largest proportion (30-65%) over the three-year time intervals. This proportion increased until 2010-2012.

Conclusion: CD4+ cell count at initiation of HAART was found to be very low, and the increase in late initiation of HAART in recent years is of concern. We think that this increase is primarily due to an increasing proportion of late presenters. We recommend early detection of HIV patients and earlier start of HAART in order to treat and prevent spread of HIV infection.

Key Words: Human immunodeficiency virus; Cohort Study; CD4+ Lymphocyte Count

Received: December 5, 2016 **Accepted:** April 17, 2017 **Published online:** June 1, 2017

Corresponding Author : Shin-Woo Kim, MD

Department of Internal Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea


Tel: +82-53-420-6525, Fax: +82-53-426-2046

E-mail: ksw2kms@knu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyrights © 2017 by The Korean Society of Infectious Diseases | Korean Society for Chemotherapy

www.icjournal.org



Introduction

Due to developments of highly active antiretroviral therapy (HAART), morbidity and mortality related to human immunodeficiency virus (HIV) infected patients has reduced markedly [1, 2]. In 2014, the number of HIV-infected patients globally was about 36.9 million (34.3 - 41.4 million), and 2 million people were newly diagnosed with HIV [3]. At this time, 15 million HIV patients were receiving HAART [3]. Previous studies have found that starting HAART when the CD4+ cell count is high is recommended for improved virologic and immunologic recovery and prevents disease progression [4-6]. Starting HAART when CD4+ cell counts are already low results in acquired immunodeficiency syndrome (AIDS) defining disease for many patients [7]; HIV-infected patients who started HAART with a CD4+ cell count <200 cells/mm³ may not reach a normal CD4+ cell count [6]. In addition, early treatment of HAART prevents sexual transmission among serodiscordant couples [8]. Considering these clinical findings, many HIV/AIDS expert groups have updated their clinical guidelines regarding the recommended time point for initiating HAART. The European AIDS Clinical Society (EACS) recommends that patients whose CD4+ cell counts are <350 cells/mm³ initiate HAART [9]. However, the Department of Health and Human Services (DHHS) guidelines strongly recommend that HIV-positive patients with CD4+ cell count ≤ 500 cells/mm³ should initiate HAART [10]. The World Health Organization (WHO) also recently updated their treatment guidelines to advise that HAART should be initiated for all HIV-positive adult patients, regardless of WHO clinical stage and CD4+ cell count [11]. Consistent with these other recommendations, the Korean Society for AIDS revised their guidelines in 2013 to recommend that all HIV-infected patients, regardless of CD4+ cell count, initiate HAART. The guidelines also favor treatment of HIV-positive patients whose infection status is acute or who were recently infected [12]. Although previous clinical data and guidelines recommend early initiation of ART, most HIV-infected patients initiate HAART when they are diagnosed with low CD4+ cell counts [2, 13, 14]. In Korea, the total number of patients infected with HIV in 2015 was 10,502 and there were 1,052 newly infected patients; incidence has been observed to be increasing steadily. In addition, with the support of the national HIV/AIDS policy, the proportion of patients treated with HAART has increased. It is necessary to know the real status of CD4+ cell count and HIV-RNA at the HIV diagnosis and HAART initiation. Therefore, we researched CD4+ cell count and HIV-RNA of Korean HIV-

infected patients at the time points of diagnosis and initiation of treatment, using Korea HIV/AIDS Cohort Study data.

Materials and Methods

The Korea HIV/AIDS Cohort Study was a prospective observational cohort study with patients from 21 tertiary or secondary hospitals in South Korea, initiated in 2006. The Korea HIV/AIDS Cohort Study collected data on HIV-infected individuals, including socioeconomic status, route of infection, HAART, conventional laboratory data, immunological and viral laboratory data, and information on opportunistic infections. The institutional review board approval was obtained from all participating hospitals.

Within the cohort study population, patients who had CD4+ cell count and HIV-RNA titer data at the time of diagnosis and HAART initiation were included in this study. Data were stratified on the basis of CD4+ cell count (≤ 100 , 101-200, 201-350, 351-500, and >500 cells/mm³) and HIV-RNA titer ($\leq 50,000$, 50,001-100,000, 100,001-200,000, 200,001-1,000,000, and $>1,000,000$ copies/mL), and analyzed by 3-year time intervals. The stratified data are presented with percentages, average values, mean values, and quartile values.

Additionally, we investigated age, sex, transmission route, and the past medical history of patients with a CD4+ cell count at the time of diagnosis. We compared these factors based on the CD4+ cell count at diagnosis (cutoff point: CD4+ cell count 200 cells/mm³ or 350 cells/mm³). The Student-*t* test or the Wilcoxon Rank-Sum test was used to analyze continuous variables, and the chi-square test or the Fisher exact test was used for categorical variables. Statistical analyses were performed using R statistics version 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria), and $P < 0.05$ was considered statistically significant.

Result

1. Trend of CD4+ cell count and HIV-RNA titer at the time of diagnosis

As of August 2015, 1,356 HIV-infected patients were enrolled in the Korea HIV/AIDS Cohort Study. Among the Cohort Study population, 1,124 HIV-infected patients were suitable for analysis of CD4+ cell count at time of diagnosis. Mean and median values of CD4+ cell counts were 271 cells/mm³ and 247 cells/mm³ (interquartile range [IQR] 104 - 390 cells/mm³),

respectively. Table 1 shows mean and median values of CD4+ cell count at HIV diagnosis, according to three-year intervals. The patients suitable for analysis comprised between 1% and 15% of new patients with HIV/AIDS in each period (Table 1). The median age at diagnosis was 40 years (overall; IQR 31-48 years); 33 years (IQR 30-41) before 2000; 42 years (IQR 35-46) between 2001 and 2003; 40 years (IQR 31-47) between 2004 and 2006; 41 years (IQR 33-50) between 2007 and 2009; 39 years (IQR 30-51) between 2010 and 2012, and; 34 years (IQR 26-44) between 2013 and 2015. The patients with CD4+ cell counts lower than 100 cells/mm³ increased until 2012 (Fig. 1). However, in the three most recent years (2013-2015), the proportion of patients with lower initial CD4+ cell counts decreased. Additionally, the number of patients with CD4+ cell counts of more than 350 cells/mm³ at the time of diagnosis has increased (Fig. 1). However, patients with CD4+ cell counts lower than 100 cells/mm³ at diagnosis were still a substantial portion (10-33%) of the cohort study population (Fig. 1). CD4+ cell counts lower than 200 cells/mm³ at diagnosis increased over time (31-51%, maximum at 2010-2012 period). CD4+ cell counts lower than 350 cells/mm³ at diagnosis increased over time as well (55-75%, maximum at 2010-2012 period).

When the subjects were classified by a CD4+ cell count of 200 cells/mm³, 467 patients were included in the CD4+ cell count ≤200 cells/mm³ group. The median age at diagnosis was higher in the group with a CD4+ cell count ≤200 cells/mm³ (41 years, interquartile range [IQR] 33-49.5) (*P* = 0.001). With respect to their past medical history, syphilis was observed more frequently in patients with a CD4+ cell count >200 cells/




Figure 1. The trend of CD4+ cell count at the time of diagnosis by 3-year intervals. As of 2015, a total of 1,124 HIV-infected patients were included. Each period was stratified by grade of CD4+ cell count: ≤100, 101-200, 201-350, 351-500, and >500 cells/mm³. Values are presented as number (percentage).

Table 1. CD4+ cell count and HIV-RNA titer at the time of HIV diagnosis, by 3-year intervals

Year	CD4+ cell count at the time of HIV diagnosis						HIV-RNA titer at the time of HIV diagnosis					
	-2000	2001-2003	2004-2006	2007-2009	2010-2012	2013-2015	-2000	2001-2003	2004-2006	2007-2009	2010-2012	2013-2015
Number of patients ^a	29 (2.2)	83 (6.6)	314 (15.4)	352 (15.3)	245 (9.7)	101 (3.2)	19 (1.5)	87 (6.9)	290 (14.2)	338 (14.7)	248 (9.8)	97 (3.1)
Mean value	334	274	292	261	236	308	59,564	121,600	317,717	453,701	615,233	168,859
Median value	326	252	269	233	195	295	24,724	38,000	24,000	43,250	76,651	36,800
Quartile	25	146	126	95	58	148	7,521	3,430	3,155	5,785	18,700	11,150
	75	471	417	375	348	441	107,304	140,000	120,000	137,750	213,759	115,900

Values are presented as cells/mm³ in CD4+ cell count and copies/mL in HIV-RNA titer.

^aValues in parentheses are the percentage of study population among new patients in Korea. HIV, human immunodeficiency virus.

mm³ (203 patients, *P* = 0.029). Tuberculosis was observed more frequently in patients with a CD4+ cell count ≤200 cells/mm³ (109 patients, *P* <0.0001) (Table 2).

When the subjects were classified by a CD4+ cell count of 350 cells/mm³, 778 patients were included in the CD4+ cell count ≤350 cells/mm³ group (low CD4+ group) and 346 patients were included in the CD4+ cell count >350 cells/mm³ group (high CD4+ group). The median age at diagnosis was 41 years in the low CD4+ group (IQR 32-49), which was higher than that of the high CD4+ group (38.5 years, IQR 31-48) (*P* = 0.038). Syphilis was observed in 213 patients in the low CD4+ group and in 109 patients in the high CD4+ group, which was not statistically significant (*P* = 0.169). Tuberculosis was ob-

Table 2. Factors associated with low CD4+ cell count in patients with HIV infection at the time of diagnosis

	CD4+ >200 (n=657)	CD4+ ≤200 (n=467)	<i>P</i> -value
Gender			0.550
Female	48 (7.3)	29 (6.2)	
Male	609 (92.7)	438 (93.8)	
Median age at diagnosis in years	39 (30-48)	41 (33-49.5)	0.001
Age at diagnosis			0.002
≤29	150 (22.8)	69 (14.8)	
30-39	199 (30.3)	130 (27.8)	
40-49	166 (25.3)	151 (32.3)	
50-59	95 (14.5)	72 (15.4)	
≥60	47 (7.2)	45 (9.6)	
Estimated transmission route			
Sexual intercourse	572 (87.1)	404 (86.5)	0.628
- MSM ^a	287 (43.7)	166 (35.5)	0.007
- Heterosexual	230 (35.0)	202 (43.3)	0.003
- Unknown	55 (8.4)	36 (7.7)	
IVDU	0 (0)	5 (1.1)	0.024
Transfusion	9 (1.4)	15 (3.2)	0.045
Injection of coagulation factor	2 (0.3)	2 (0.4)	1.000
Unknown	74 (11.3)	41 (8.8)	
Past medical history			
HBV infection	34 (5.2)	19 (4.1)	0.464
HCV infection	6 (0.9)	5 (1.1)	1.000
Syphilis	203 (30.9)	119 (25.5)	0.029
Gonorrhea	43 (6.5)	30 (6.4)	1.000
Non-gonococcal urethritis	38 (5.8)	24 (5.1)	0.754
Tuberculosis	72 (11.0)	109 (23.3)	<0.0001

Values are presented as median (interquartile range) or number (%).

^aMSM included homosexual or bisexual.

HIV, human immunodeficiency virus; MSM, men who have sex with men; IVDU, intravenous drug user; HBV, hepatitis B virus; HCV, hepatitis C virus.

served more frequently in the low CD4+ group (148/778) [19%] than in the high CD4+ group (33/346) [9.5%] (*P* <0.0001).

A total of 1,079 HIV-infected patients met the criteria for analysis of HIV-RNA titer at the time of diagnosis. Mean and median values of HIV-RNA titer were 394,955 copies/mL and 39,436 copies/mL (IQR, 7,150-151,000 copies/mL), respectively. Until the 2010-2012 period, the proportion of patients with HIV-RNA <50,000 copies/mL decreased (Fig. 2).

2. Trend of CD4+ cell count and HIV-RNA titer at the time of initiating HAART

A total of 376 HIV-infected patients met the criteria for analysis of CD4+ cell count at time of initiating HAART. Mean and median values of CD4+ cell counts were 194 cells/mm³ and 181 cells/mm³ (IQR, 63-270 cells/mm³), respectively. Median value of CD4+ cell count was lowest in 2010-2012 period, and those values showed a decrease pattern until 2010-2012 period (Table 3).

The overall trend found was that the proportion of patients whose CD4+ cell count at initiation of HAART was over 350 cells/mm³ has decreased (Fig. 3), whereas, the proportion of patients with CD4+ cell counts lower than 350 cells/mm³ at initiation of HAART has increased. In addition, the proportion of patients with CD4+ cell counts lower than 100 cells/mm³ at initiation of HAART has increased; in 2010-2012 period, those patients account for 43% (Fig. 3). CD4+ cell counts lower than 200 cells/mm³ at initiation of HAART showed increasing tendency (30-65%, maximum at 2010-2012 period).

A total of 322 HIV-infected patients met the criteria for anal-




Figure 2. The trend of HIV-RNA titer at the time of diagnosis by 3-year intervals. As of 2015, a total of 1,079 HIV-infected patients were included. Each period was stratified by the level of HIV-RNA titer: ≤50,000, 50,001-100,000, 100,001-200,000, 200,001-1,000,000, and >1,000,000 copies/mL. Values are presented as number (percentage).

Table 3. CD4+ cell count and HIV-RNA titer at the time of initiating highly active antiretroviral therapy, by 3-year intervals

Year	CD4+ cell count at the time of initiating HAART						HIV-RNA titer at the time of initiating HAART					
	- 2000	2001-2003	2004-2006	2007-2009	2010-2012	2013-2015	- 2000	2001-2003	2004-2006	2007-2009	2010-2012	2013-2015
Number of patients	12	48	127	110	69	10	3	38	104	102	66	9
Mean value	229	212	213	172	156	320	11,103	179,463	696,943	419,355	603,373	343,503
Median value	232	192	195	153	120	246	8,021	93,400	94,500	65,972	119,500	110,000
Quartile	25	135	116	60	38	179	289	18,105	16,167	10,300	35,025	18,665
	75	307	284	258	237	453	25,000	213,500	498,500	260,000	315,250	705,501

Values are presented as cells/mm³ in CD4+ cell count and copies/mL in HIV-RNA titer. HIV, human immunodeficiency virus; HAART, highly active antiretroviral therapy.




Figure 3. The trend of CD4+ cell count at the time of initiating highly active antiretroviral therapy by 3-year intervals. As of 2015, 376 HIV patients were included. CD4+ cell count, ≤ 100, 101-200, 201-350, 351-500, and >500 cells/mm³, is stratified for each time interval. Values are presented as number (percentage).




Figure 4. The trend of HIV-RNA titer at the time of initiating highly active antiretroviral therapy by three-year intervals. As of 2015, 322 HIV patients were included. Level of HIV-RNA: ≤ 50,000; 50,001-100,000; 100,001-200,000; 200,001- 1,000,000; and >1,000,000 copies/mL is stratified for each time interval. Values are presented as number (percentage).

ysis of HIV-RNA titers at initiation of HAART. The mean and median values of HIV-RNA titers were 493,116 copies/mL and 83,500 copies/mL (IQR, 15,763-292,500 copies/mL), respectively. The proportion of patients with HIV-RNA <50,000 copies/mL has steadily decreased, and patients with high RNA titer at treatment has increased (Fig. 4).

Discussion

Based on Korea HIV/AIDS Cohort Study data, we found from our analysis that patients whose CD4+ cell count at the time of diagnosis was lower than 350 cells/mm³ accounted for

over half of all patients. In particular, the proportion of patients with CD4+ cell count ≤ 100 cells/mm³ at the time of diagnosis has steadily increased from 2000 to the 2010-2012 time interval. In other Korea HIV data from the Korea National Institute of Health, the proportion of patients with CD4+ T cell count < 200 cells/mm³ increased from before 1993 to the period of 2004 to 2006 [15]. Similar to previous reports, our cohort data showed gradual increase of patients with CD4+ cell count < 200 cells/mm³. Presentation of CD4+ cell count lower than 350 cells/ μ L at the time of diagnosis has also been found in other countries. In northwest Spain data from 2004-2013, 53.1% of newly infected HIV patients had low CD4+ cell counts (CD4+ count < 350 cells/mm³) [16]. In the United Kingdom, 49% of newly infected HIV patients in 2011 were diagnosed at a low CD4+ cell count, lower than 350 cells/mm³ [17]. Shen et al. reported the CD4+ cell count at the time of diagnosis in China. From 2009-2010, about 72% of patients had a low CD4+ cell count, ≤ 200 cells/mm³, which was lower than in our report [18].

Our study showed that many patients initiated HAART at a low CD4+ cell count. The proportion of patients with a low CD4+ cell count at time of HAART initiation gradually increased until recently. We think that this result is influenced by an increase in patients with low CD4+ cell count at the time of diagnosis. More patients with CD4+ cell count ≤ 100 cells/ μ L at time of diagnosis have been observed, and this tendency has increased over time.

In contrast to our national trends, recent reports from Asia showed a tendency towards increased CD4+ cell count at initiation of treatment. The TAHOD-TASER Cohort Study reported trends of CD4+ cell count at the initiation of HAART over time. Before 2010, median CD4+ cell count at the start of treatment was lower than 200 cells/mm³. Since 2011, median CD4+ cell count has been increasing substantially. The median CD4+ cell count in 2011 and after 2011 was 249 cells/mm³ and 302 cells/mm³, respectively. In addition, the proportion of patients with CD4+ cell count < 200 cells/mm³ at initiation of HAART markedly decreased over time, from 82.4% in 2007 to 36.3% after 2011 [2]. This CD4+ cell count trend was similar to the findings from a study performed in Shanghai, China. The median CD4+ cell count had increased from 65 cells/mm³ in 2006 to 203 cells/mm³ in 2011. The proportion of patients with CD4+ cell count < 200 cells/mm³ decreased from 88.5% in 2006 to 49.6% in 2011 [19]. In Rwanda, an upswing in the median CD4+ cell count at HAART initiation was observed. While the median CD4+ cell count was 183 cells/mm³ in 2007, the median CD4+ cell count was 293 cells/mm³ in 2011-2012.

The proportion of patients with advanced HIV disease (CD4+ cell count < 200 cells/mm³ or WHO stage IV) had decreased from 66.2% to 29.4% [20]. In these three studies, the proportion of patients with CD4+ cell count < 200 cells/mm³ at HAART initiation, after 2010, was similar to our findings. However, the findings showed improvement in CD4+ cell counts at HAART initiation, which was in contrast to what we observed in our cohort data. Research from industrialized countries show a stable median CD4+ cell count over 300 cells/mm³ at HAART initiation for a period of about twenty years [21, 22]. In this study, consistent low median CD4+ cell counts have been observed, which were lower than those observed in other developed countries.

Upon comparing the factors based on the CD4+ cell count at diagnosis (cutoff point: 200 cells/mm³ or 350 cells/mm³), the median age at diagnosis was higher in patients with a low CD4+ cell count than in patients with a high CD4+ cell count. In addition, between 2001 and 2012, the median age at diagnosis for each period was high. Among the associated risk factors, a history of tuberculosis was observed more frequently in patients with a low CD4+ cell count. This finding may be associated with the risk of opportunistic tuberculous infection. Moreover, sexual contact among males and a history of syphilis were more frequently recorded in patients with a high CD4+ cell count. This finding suggests that the opportunity of diagnostic test would have influenced the rate of low CD4+ cell count at diagnosis.

Our study has limitations. The size of the study population, when divided into each three-year interval time period, was small. However, we believe our cohort data provides an understanding of early-stage immune status of Korean HIV patients, as well as CD4+ status at initial treatment.

In summary, the Korea HIV/AIDS Cohort Study population comprised patients who had CD4+ cell count and HIV-RNA titer values at the time of diagnosis and initiation of HAART. Our findings, based on analysis of cohort study data, suggest that early detection of HIV patients and earlier initiation of HAART, to treat and prevent the spread of HIV infection, is needed.

Acknowledgments

This study was supported by a grant for the Chronic Infectious Disease Cohort Study (Korea HIV/AIDS Cohort Study, 2016-E51003-00) from the Korea Centers for Disease Control and Prevention. We thank the members of the Korea HIV/

AIDS Cohort. The Korea HIV/AIDS Cohort study group consists of Min Ja Kim, Jang Wook Sohn, Young Kyung Yoon, Jun Hee Woo, Sang Il Kim, Youn Jeong Kim, Dae Won Park, Won Suk Choi, Seong-Heon Wie, Ji-An Hur, Shin-Woo Kim, Hyun-Ha Chang, Min Jung Kim, Sang Ah Lee, Woo-Joo Kim, Joon-Young Song, Joong Shik Eom, Jin Seo Lee, So Yeon Park, Hye Won Jeong, Jin-Soo Lee, Ji Hyeon Baek, Hee Jung Choi, June Myung Kim, Jun Yong Choi, Nam Su Ku, Hyo-Youl Kim, Young Hwa Choi, Eun Jung Lee, Tae Hyong Kim, Bo Youl Choi, Mee-Kyung Kee, Chun Kang, and Ju-yeon Choi.

Conflicts of Interest

No conflicts of interest.

ORCID

Min Jung Kim <https://orcid.org/0000-0002-2637-7979>
Shin-Woo Kim <https://orcid.org/0000-0002-3755-8249>
Hyun-Ha Chang <https://orcid.org/0000-0002-9405-2121>

Reference

1. Hermans SM, van Leth F, Manabe YC, Hoepelman AI, Lange JM, Kambugu A. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study. *HIV Med* 2012;13:337-44.
2. Kiertiburanakul S, Boettiger D, Lee MP, Omar SF, Tanuma J, Ng OT, Durier N, Phanuphak P, Ditangco R, Chaiwarith R, Kantipong P, Lee CK, Mustafa M, Saphonn V, Ratanasuwann W, Merati TP, Kumarasamy N, Wong WW, Zhang F, Pham TT, Pujari S, Choi JY, Yunihastuti E, Sungkanuparph S; TREAT Asia HIV Observational Databases (TAHOD); TREAT Asia Studies to Evaluate Resistance (TASER). Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients. *J Int AIDS Soc* 2014;17:18804.
3. World Health Organization (WHO). Fact sheet: 2014 statistics. Available at: http://www.unaids.org/en/resources/documents/2015/20150714_factsheet. Accessed 24 August 2015.
4. Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayehu M, Kindeya F. CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study. *PLoS One* 2015;10:e0122583.
5. Yamashita TE, Phair JP, Muñoz A, Margolick JB, Detels R, O'Brien SJ, Mellors JW, Wolinsky SM, Jacobson LP. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. *AIDS* 2001;15:735-46.
6. Kelley CE, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. *Clin Infect Dis* 2009;48:787-94.
7. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, Cavert WP, Henry WK, Neaton JD; Terry Bein Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. *AIDS* 2008;22:841-8.
8. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaud H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011;365:493-505.
9. European AIDS Clinical Society (EACS). The European Guidelines for treatment of HIV infected adults in Europe. Available at: http://www.eacsociety.org/files/2015_eacs-guidelines_8.0-english_revised-20151104.pdf. Accessed 4 November 2015.
10. Department of Health and Human Services (HHS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: <https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescent-gl.pdf>. Accessed 8 April 2015.
11. World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Available at: http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf. Accessed 30 September 2015.
12. The Korean Society for AIDS. The 2013 clinical guidelines for the diagnosis and treatment of HIV/AIDS in HIV-infected Koreans. *Infect Chemother* 2013;45:455-61.

13. Kiertiburanakul S, Boonyarattaphun K, Atamasirikul K, Sungkanuparph S. Clinical presentations of newly diagnosed HIV-infected patients at a university hospital in Bangkok, Thailand. *J Int Assoc Physicians AIDS Care (Chic)* 2008;7:82-7.
14. Korean Society for AIDS. The 2015 clinical guidelines for the treatment and prevention of opportunistic infections in HIV-infected Koreans: guidelines for opportunistic infections. *Infect Chemother* 2016;48:54-60.
15. Kee MK, Lee JH, Kim GJ, Choi BS, Hong KJ, Lee JS, Kim SS. Decrease of initial CD4+ T-cell counts at the time of diagnosis of HIV infection in Korea; 1988-2006. *Int J STD AIDS* 2010;21:120-5.
16. Pernas B, Mena A, Cañizares A, Grandal M, Castro-Iglesias A, Pértega S, Pedreira JD, Poveda E. Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years. *J Med Virol* 2015;87:1319-26.
17. Delpech V, Brown AE, Croxford S, Chau C, Polavarapu V, Cooper N, Rooney G, Yin Z. Quality of HIV care in the United Kingdom: key indicators for the first 12 months from HIV diagnosis. *HIV Med* 2013;14 (Suppl 3):19-24.
18. Shen Y, Lu H, Wang Z, Qi T, Wang J. Analysis of the immunologic status of a newly diagnosed HIV positive population in China. *BMC Infect Dis* 2013;13:429.
19. Shen Y, Wang J, Qi T, Wang Z, Lu H. Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011. *Int J STD AIDS* 2013;25:504-10.
20. Mutimura E, Addison D, Anastos K, Hoover D, Dusingize JC, Karenzie B, Izimukwiye I, Mutesa L, Nsanzimana S, Nash D; IeDEA Central Africa Collaboration. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda. *AIDS* 2015;29:67-76.
21. Miranda AC, Moneti V, Brogueira P, Peres S, Baptista T, Aldir I, Ventura F, Borges F, Mansinho K. Evolution trends over three decades of HIV infection late diagnosis: the experience of a Portuguese cohort of 705 HIV-infected patients. *J Int AIDS Soc* 2014;17 (4 Suppl 3):19688.
22. Lesko CR, Cole SR, Zinski A, Poole C, Mugavero MJ. A systematic review and meta-regression of temporal trends in adult CD4(+) cell count at presentation to HIV care, 1992-2011. *Clin Infect Dis* 2013;57:1027-37.